CN101855210A - 用作电压-门控钠通道抑制剂的酰胺类 - Google Patents

用作电压-门控钠通道抑制剂的酰胺类 Download PDF

Info

Publication number
CN101855210A
CN101855210A CN200880115687A CN200880115687A CN101855210A CN 101855210 A CN101855210 A CN 101855210A CN 200880115687 A CN200880115687 A CN 200880115687A CN 200880115687 A CN200880115687 A CN 200880115687A CN 101855210 A CN101855210 A CN 101855210A
Authority
CN
China
Prior art keywords
pain
ring
group
compound
aliphatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880115687A
Other languages
English (en)
Chinese (zh)
Inventor
W·C·陈
P·克任尼特斯奇
A·特明
D·威尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101855210A publication Critical patent/CN101855210A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN200880115687A 2007-10-11 2008-10-10 用作电压-门控钠通道抑制剂的酰胺类 Pending CN101855210A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97929207P 2007-10-11 2007-10-11
US60/979,292 2007-10-11
PCT/US2008/079544 WO2009049181A1 (en) 2007-10-11 2008-10-10 Amides useful as inhibitors of voltage-gated sodium channels

Publications (1)

Publication Number Publication Date
CN101855210A true CN101855210A (zh) 2010-10-06

Family

ID=40373424

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880115687A Pending CN101855210A (zh) 2007-10-11 2008-10-10 用作电压-门控钠通道抑制剂的酰胺类

Country Status (13)

Country Link
US (2) US8389734B2 (https=)
EP (1) EP2212292B1 (https=)
JP (1) JP5436434B2 (https=)
KR (1) KR20100066583A (https=)
CN (1) CN101855210A (https=)
AU (1) AU2008310661A1 (https=)
CA (1) CA2701766A1 (https=)
IL (1) IL204977A0 (https=)
MX (1) MX2010003864A (https=)
NZ (1) NZ584474A (https=)
RU (1) RU2010118481A (https=)
WO (1) WO2009049181A1 (https=)
ZA (1) ZA201002471B (https=)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429571A (zh) * 2010-12-22 2013-12-04 普渡制药公司 作为钠通道阻断剂的取代吡啶
CN104968647A (zh) * 2013-01-31 2015-10-07 沃泰克斯药物股份有限公司 作为钠通道调节剂的酰胺
CN105814067A (zh) * 2013-12-13 2016-07-27 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺的前药
CN108164457A (zh) * 2013-01-31 2018-06-15 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
CN110885328A (zh) * 2018-09-10 2020-03-17 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
CN111065383A (zh) * 2017-07-11 2020-04-24 沃泰克斯药物股份有限公司 用作钠通道调节剂的羧酰胺
CN112390745A (zh) * 2019-08-19 2021-02-23 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
CN112479996A (zh) * 2019-09-12 2021-03-12 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
CN113045487A (zh) * 2019-12-27 2021-06-29 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
WO2024032774A1 (zh) * 2022-08-12 2024-02-15 广州费米子科技有限责任公司 用作电压-门控钠通道抑制剂的化合物
WO2024217344A1 (zh) * 2023-04-19 2024-10-24 中国科学院上海药物研究所 Nav1.8抑制剂及其制备方法和用途

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163499A2 (en) * 2010-06-23 2011-12-29 Opko Curna, Llc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
ES2532357T3 (es) 2010-07-12 2015-03-26 Pfizer Limited Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
EP2593433B1 (en) 2010-07-12 2014-11-26 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2016501203A (ja) 2012-11-20 2016-01-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物
CN105073738B (zh) * 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
ES2654393T3 (es) 2013-07-19 2018-02-13 Vertex Pharmaceuticals Incorporated Sulfonamidas como moduladores de los canales de sodio
US20150301030A1 (en) * 2014-04-22 2015-10-22 Q-State Biosciences, Inc. Models for parkinson's disease studies
US10048275B2 (en) 2015-03-13 2018-08-14 Q-State Biosciences, Inc. Cardiotoxicity screening methods
WO2016187543A1 (en) 2015-05-21 2016-11-24 Q-State Biosciences, Inc. Optogenetics microscope
EP3359151A4 (en) * 2015-10-07 2019-08-14 Arizona Board of Regents on behalf of the University of Arizona CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF
CN109640657B (zh) * 2016-07-07 2020-10-30 美国陶氏益农公司 制备4-烷氧基-3-(酰基或脂族饱和烃基)氧基吡啶甲酰胺的方法
AU2019301628C1 (en) * 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
AU2019302534B2 (en) 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
WO2020092187A1 (en) * 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
EP3873893A1 (en) 2018-11-02 2021-09-08 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2020146612A1 (en) * 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
GEP20257750B (en) 2020-06-17 2025-03-25 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
JP2023530319A (ja) 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害剤としての２－オキソ－オキサゾリジン－５－カルボキサミド
EP4334293A1 (en) 2021-05-07 2024-03-13 Merck Sharp & Dohme LLC Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
TW202317520A (zh) 2021-06-15 2023-05-01 德商歌林達有限公司 經取代之吡唑醯胺
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor
EP4385984A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Pyridine-n-oxides as inhibitors of nav1.8
EP4385980A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Indazoles as inhibitors of nav1.8
AR131345A1 (es) 2022-12-14 2025-03-12 Gruenenthal Gmbh SULFOXIMINAS COMO INHIBIDORES DE NaV1.8
EP4385979A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Multicyclic inhibitors of nav1.8

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE568114A (https=) 1957-05-29 1900-01-01
ES482591A1 (es) 1978-07-20 1980-04-01 Basf Ag Procedimiento para la obtencion de n-arilsulfonilpirroles.
US4228449A (en) * 1978-12-26 1980-10-14 Hughes Aircraft Company Semiconductor diode array liquid crystal device
US6620849B2 (en) 2000-07-26 2003-09-16 Icafen, Inc. Potassium channel inhibitors
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
AU2002363250A1 (en) 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2004106324A1 (en) 2003-05-27 2004-12-09 E.I. Dupont De Nemours And Company Azolecarboxamide herbicides
MXPA05013434A (es) * 2003-06-12 2006-03-17 Astellas Pharma Inc Derivados de benzamida o sal del mismo.
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US8202861B2 (en) * 2003-08-08 2012-06-19 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
EP1819341A4 (en) 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp IL-12 MODULATORY CONNECTIONS
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
CA2648202A1 (en) * 2006-04-11 2007-10-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
US8383734B2 (en) * 2006-07-17 2013-02-26 Syracuse University Multi-solution bone cements and methods of making the same

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429571A (zh) * 2010-12-22 2013-12-04 普渡制药公司 作为钠通道阻断剂的取代吡啶
US11673864B2 (en) 2013-01-31 2023-06-13 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
TWI714967B (zh) * 2013-01-31 2021-01-01 美商維泰克斯製藥公司 作為鈉通道調節劑之吡啶酮醯胺
CN104968647B (zh) * 2013-01-31 2018-01-26 沃泰克斯药物股份有限公司 作为钠通道调节剂的酰胺
CN104968647A (zh) * 2013-01-31 2015-10-07 沃泰克斯药物股份有限公司 作为钠通道调节剂的酰胺
CN108164457A (zh) * 2013-01-31 2018-06-15 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
US10738009B2 (en) 2013-01-31 2020-08-11 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
TWI655187B (zh) * 2013-01-31 2019-04-01 維泰克斯製藥公司 作爲鈉通道調節劑之吡啶酮醯胺
CN108164457B (zh) * 2013-01-31 2021-07-09 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺
TWI659945B (zh) * 2013-01-31 2019-05-21 維泰克斯製藥公司 作爲鈉通道調節劑之醯胺
TWI668226B (zh) * 2013-12-13 2019-08-11 美商維泰克斯製藥公司 作為納通道調節劑之吡啶酮醯胺之前藥
TWI651329B (zh) * 2013-12-13 2019-02-21 美商維泰克斯製藥公司 作為鈉通道調節劑之吡啶酮醯胺之前藥
TWI703154B (zh) * 2013-12-13 2020-09-01 美商維泰克斯製藥公司 作為鈉通道調節劑之吡啶酮醯胺之前藥
US10787472B2 (en) 2013-12-13 2020-09-29 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US11773119B2 (en) 2013-12-13 2023-10-03 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
CN105814067B (zh) * 2013-12-13 2018-05-18 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺的前药
US10253054B2 (en) 2013-12-13 2019-04-09 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
CN105814067A (zh) * 2013-12-13 2016-07-27 沃泰克斯药物股份有限公司 作为钠通道调节剂的吡啶酮酰胺的前药
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
US12281057B2 (en) 2017-07-11 2025-04-22 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CN111065383A (zh) * 2017-07-11 2020-04-24 沃泰克斯药物股份有限公司 用作钠通道调节剂的羧酰胺
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
CN110885328B (zh) * 2018-09-10 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
CN110885328A (zh) * 2018-09-10 2020-03-17 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
CN112390745A (zh) * 2019-08-19 2021-02-23 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
CN113906013A (zh) * 2019-09-12 2022-01-07 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
WO2021047622A1 (zh) * 2019-09-12 2021-03-18 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
CN112479996A (zh) * 2019-09-12 2021-03-12 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
CN112479996B (zh) * 2019-09-12 2023-05-26 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
CN113906013B (zh) * 2019-09-12 2024-03-12 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US12247021B2 (en) 2019-12-06 2025-03-11 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11919887B2 (en) 2019-12-06 2024-03-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
CN113045487A (zh) * 2019-12-27 2021-06-29 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
US12258333B2 (en) 2021-06-04 2025-03-25 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
WO2024032774A1 (zh) * 2022-08-12 2024-02-15 广州费米子科技有限责任公司 用作电压-门控钠通道抑制剂的化合物
US12521399B2 (en) 2022-08-12 2026-01-13 Guangzhou Fermion Technology Co., Ltd. Compound as voltage-gated sodium channel inhibitor
WO2024217344A1 (zh) * 2023-04-19 2024-10-24 中国科学院上海药物研究所 Nav1.8抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
AU2008310661A1 (en) 2009-04-16
US8389734B2 (en) 2013-03-05
NZ584474A (en) 2012-06-29
EP2212292A1 (en) 2010-08-04
RU2010118481A (ru) 2011-11-20
US20130231370A1 (en) 2013-09-05
WO2009049181A1 (en) 2009-04-16
US8865771B2 (en) 2014-10-21
CA2701766A1 (en) 2009-04-16
KR20100066583A (ko) 2010-06-17
MX2010003864A (es) 2010-06-01
JP2011500599A (ja) 2011-01-06
EP2212292B1 (en) 2012-12-05
US20090118333A1 (en) 2009-05-07
JP5436434B2 (ja) 2014-03-05
IL204977A0 (en) 2010-11-30
ZA201002471B (en) 2011-06-29

Similar Documents

Publication Publication Date Title
EP2212292B1 (en) Amides useful as inhibitors of voltage-gated sodium channels
EP2212290B1 (en) Aryl amides useful as inhibitors of voltage-gated sodium channels
EP2227453B1 (en) Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
JP2012126744A (ja) イオンチャネルのモジュレーターとしての二環式の誘導体
KR20080015102A (ko) 이온 채널 조절인자로서의 바이사이클릭 유도체
AU2008302205A1 (en) Pyridyl sulfonamides as modulators of ion channels
KR20080019693A (ko) 이온 채널 조절인자로서의 인단 유도체
KR20080059292A (ko) 전압 개폐 이온 채널 조절인자로서의 바이페닐 유도체
KR20080044910A (ko) 전압 개폐 이온 채널 조절인자로서의 바이사이클릭 유도체
HK1144807A (en) Amides useful as inhibitors of voltage-gated sodium channels
HK1145325A (en) Aryl amides useful as inhibitors of voltage-gated sodium channels
HK1145180A (en) Heteroaryl amides useful as inhibitors of voltage-gated sodium channels

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1144807

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101006

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1144807

Country of ref document: HK